Guardian Science Weekly

Trump is backing psychedelic research: here’s why

Loading player...
Last month President Trump signed an executive order designed to fast track both research and access to psychedelic drugs as treatments for mental health illnesses. The most prominent in the order was ibogaine, a drug derived from the root bark of a West African shrub, that has shown some promise in relieving the long term effects of traumatic brain injury. Madeleine Finlay talks to journalist Mattha Busby about podcaster Joe Rogan’s role in the story, what else is behind the President’s interest in psychedelic research, and what the order will change in practice for scientists and researchers. Help support our independent journalism at theguardian.com/sciencepod
12 May English United Kingdom Science · Nature

Other recent episodes

Can a name change transform PCOS outcomes for women?

After more than a decade of global consultation, polycystic ovary syndrome – which affects as many as one in eight women – has been renamed. The condition is caused by high levels of androgens, which can lead to symptoms such as excess hair, weight gain and irregular periods. To understand…
21 May 16 min

Ebola outbreak: what do we know and can it be contained?

An outbreak of Ebola has emerged in the Democratic Republic of Congo and Uganda, which has led to nearly 400 confirmed cases and more than 100 deaths. To find out how the outbreak might have begun, what authorities can do to contain it and why this outbreak is causing particular…
18 May 13 min

Hantavirus update, Pentagon’s UFO files, can art slow biological ageing?

Madeleine Finlay sits down with co-host and science editor Ian Sample to discuss three eyecatching stories from the week, including an update on hantavirus. Also on the agenda is the Pentagon’s release of a tranche of never before seen documents relating to UFOs, and a study looking at the link…
14 May 21 min
All episodes